Profile data is unavailable for this security.
About the company
Windlas Biotech Limited is a domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). Its portfolio of CDMO solutions includes product development, licensing, and commercial manufacturing of complex drugs and dosage forms. Its product development and manufacturing capabilities in complex generic products by developing products, including alternate dosages, such as, medicated mouth sprays; coating technologies, including, pellet coating using bottom spray, API coating, pH dependent coating and nanosized crystals; nutraceuticals dosages, including, biscuits, protein powder, supplements, chocolate bars and malt based foods, and ayurvedic products, such as wellness products, hair oils and cough syrups. Its four fungible, Schedule-M compliant OSD/OLD manufacturing facilities are located in Dehradun, Uttarakhand, India. It specializes in manufacturing formulations, solid pharmaceutical dosage forms, liquid pharmaceutical dosage forms and injectables.
- Revenue in INR (TTM)8.68bn
- Net income in INR667.47m
- Incorporated2001
- Employees1.35k
- LocationWindlas Biotech Ltd40/1 Mohabewala Industrial AreaGURGAON 122001IndiaIND
- Phone+91 1 242821030
- Websitehttps://windlas.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd | 2.82bn | 409.03m | 11.68bn | 1.40k | 28.75 | -- | 23.20 | 4.15 | 6.07 | 6.07 | 41.76 | -- | -- | -- | -- | 2,012,738.00 | -- | 14.71 | -- | 17.26 | 63.66 | 60.59 | 14.53 | 12.54 | -- | 44.64 | -- | 39.88 | 28.76 | 11.13 | 146.45 | 47.72 | -28.44 | 65.72 |
| Lincoln Pharmaceuticals Ltd | 6.52bn | 878.34m | 13.11bn | 1.85k | 14.92 | -- | 12.86 | 2.01 | 43.86 | 43.86 | 325.55 | -- | -- | -- | -- | 3,518,272.00 | -- | 13.22 | -- | 15.46 | 53.64 | 50.82 | 13.47 | 14.56 | -- | 77.35 | -- | 3.32 | 7.35 | 10.03 | -11.74 | 9.87 | 20.13 | -- |
| Syncom Formulations (India) Ltd | 5.15bn | 630.52m | 13.14bn | 554.00 | 20.26 | 3.47 | 19.23 | 2.55 | 0.69 | 0.69 | 5.56 | 4.03 | 1.24 | 8.89 | 5.41 | 9,296,547.00 | 15.22 | 8.56 | 17.65 | 11.58 | 36.52 | 34.81 | 12.24 | 10.15 | 4.24 | 73.92 | 0.0018 | -- | 76.55 | 17.74 | 95.28 | 28.24 | 41.62 | -- |
| Hester Biosciences Ltd | 3.14bn | 409.47m | 13.31bn | 562.00 | 41.52 | -- | 22.32 | 4.23 | 37.69 | 37.69 | 277.25 | -- | -- | -- | -- | 5,594,555.00 | -- | 5.39 | -- | 6.72 | 73.52 | 64.87 | 13.51 | 11.44 | -- | 9.65 | -- | 23.77 | 2.15 | 11.16 | 45.52 | -1.18 | -22.47 | 1.18 |
| Beta Drugs Ltd | 3.86bn | 464.68m | 13.87bn | 399.00 | 19.70 | 6.27 | 22.64 | 3.60 | 69.72 | 65.19 | 509.33 | 218.94 | 0.986 | 3.64 | 3.48 | 9,665,303.00 | 11.88 | 15.08 | 16.29 | 21.53 | 39.79 | 40.30 | 12.05 | 12.72 | 2.45 | 5.13 | 0.3974 | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 14.07bn | 456.00 | 39.77 | -- | 26.43 | 3.15 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Windlas Biotech Ltd | 8.68bn | 667.47m | 16.97bn | 1.35k | 25.59 | -- | 17.34 | 1.95 | 31.46 | 31.46 | 409.16 | -- | -- | -- | -- | 6,450,929.00 | -- | 8.65 | -- | 11.81 | 38.34 | 34.09 | 7.69 | 7.70 | -- | 15.80 | -- | 18.33 | 20.43 | 18.24 | 4.82 | 30.34 | 27.99 | -- |
| Amrutanjan Health Care Ltd | 4.88bn | 569.03m | 18.38bn | 631.00 | 32.31 | -- | 29.07 | 3.76 | 19.68 | 19.68 | 168.85 | -- | -- | -- | -- | 7,736,897.00 | -- | 15.84 | -- | 19.67 | 50.87 | 52.17 | 11.66 | 13.26 | -- | 319.69 | -- | 19.82 | 7.26 | 11.56 | 13.03 | 15.17 | 69.46 | 26.76 |
| Indoco Remedies Ltd | 17.58bn | -1.14bn | 18.67bn | 6.05k | -- | -- | 292.20 | 1.06 | -12.52 | -12.52 | 197.86 | -- | -- | -- | -- | 2,905,519.00 | -- | 4.84 | -- | 6.87 | 71.18 | 65.70 | -6.62 | 5.16 | -- | -0.3334 | -- | 17.11 | -8.38 | 8.51 | -174.89 | -- | 43.53 | -7.79 |
| Morepen Laboratories Ltd | 17.87bn | 994.48m | 21.12bn | 1.81k | 21.24 | -- | 14.33 | 1.18 | 1.81 | 1.81 | 32.65 | -- | -- | -- | -- | 9,850,214.00 | -- | 8.14 | -- | 12.81 | 33.71 | 31.83 | 5.61 | 5.91 | -- | 5.59 | -- | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Panacea Biotec Ltd | 6.04bn | -72.40m | 21.44bn | 1.29k | -- | 2.59 | 81.72 | 3.55 | -1.18 | -1.18 | 98.44 | 134.92 | 0.4836 | 1.38 | 8.67 | 4,681,039.00 | -0.6085 | 13.08 | -0.8291 | 19.61 | 58.47 | 48.06 | -1.26 | 30.99 | 0.9785 | -14.33 | 0.0271 | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 16.47bn | 953.20m | 21.94bn | 2.89k | 23.00 | -- | 14.27 | 1.33 | 3.25 | 3.25 | -- | -- | -- | -- | -- | 5,696,991.00 | -- | 10.26 | -- | 13.42 | 34.43 | 32.57 | 5.79 | 9.33 | -- | 8.05 | -- | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Solara Active Pharma Sciences Ltd | 12.55bn | -191.10m | 22.08bn | 1.78k | -- | -- | 28.01 | 1.76 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
Data as of Feb 16 2026. Currency figures normalised to Windlas Biotech Ltd's reporting currency: Indian Rupee INR
8.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2024 | 1.31m | 6.21% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 177.20k | 0.84% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jan 2026 | 156.67k | 0.74% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 36.29k | 0.17% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 19.64k | 0.09% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 2.68k | 0.01% |
| DFA Australia Ltd.as of 31 Dec 2025 | 1.34k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 235.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
